All In Biotech

Free tool

FAERS Monitor: Isovue-250

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018735 or its brand name (Isovue-250, Iopamidol). Reports on generic versions are filed under their own applications.

Reports

2,986

Serious

2,177

73% of reports

Hospitalization

1,067

Death reported

263

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea192
  • urticaria191
  • anaphylactic reaction186
  • pruritus174
  • nausea165
  • contrast media reaction145
  • no adverse event145
  • vomiting124
  • acute kidney injury116
  • hypersensitivity110
  • off label use98
  • dizziness89
  • erythema86
  • cough81
  • anaphylactic shock78

Reports by year received

View as table
YearReports
200432
200536
20067
200720
200825
200924
201059
201183
201278
2013136
2014155
2015156
2016164
2017208
2018207
2019282
2020172
2021193
2022186
2023140
2024169
2025185
2026269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,173 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
contrast media reactionSignal145461.1391.362,058
anaphylactic reactionSignal18623.820.74,035
anaphylactic shockSignal7821.417.21,492
urticariaSignal1918.07.01,178
no adverse eventSignal1455.64.8553
acute kidney injurySignal1165.34.5408
hypersensitivitySignal1104.23.5265
pruritusSignal1743.22.8264
erythemaSignal862.92.4110
dyspnoeaSignal1922.42.1158
coughSignal812.01.642
vomiting1241.91.649
nausea1651.51.325
dizziness891.31.05
off label use980.80.66

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.